Global specialty injectables market to 2028 – by drug type, application, distribution channel and region

0

Dublin, May 20, 2022 (GLOBE NEWSWIRE) — The “Specialty Injectables Market, by Drug Type, by Application, by Distribution Channel, and by Region – Size, Share, Outlook, and Opportunity Analysis, 2021-2028” report has been added to from ResearchAndMarkets.com offer.

The specialty injectable is an expensive drug therapy that requires administration by injection. This drug is indicated for the treatment of chronic or life-threatening diseases such as human immunodeficiency virus (HIV), rheumatoid arthritis, hemophilia, cancer, cardiovascular disease, infectious disease, autoimmune disorders and other diseases.

Supervision, counseling, or aftercare are all necessary when using specialized injectables. Specialty injectables are expensive drugs that require precise temperature control, special handling, and clinical management to ensure drug performance.

Market dynamics

Market players are happy to obtain approval from regulatory authorities for their products indicated for chronic or rare diseases. This is expected to drive the growth of the global specialty injectables market over the forecast period. For example, on August 6, 2021, Sanofi, a pharmaceutical company that develops products for therapeutic treatments, received US Food and Drug Administration (FDA) approval for Nexviazyme which is used for pump disease. , a disordered inherited disease where the glycogen complex sugar is increased using Nexviazyme, has been approved based on positive results from the Phase 3 clinical trial where Nexviazyme targets the M6P receptor which eliminates glycogen buildup in muscle cells.

The market players are engaging in getting approvals for their products from the regulatory authorities which is expected to boost the market growth over the forecast period. For example, on December 23, 2020, Roche, a diagnostics and pharmaceutical company, announced European Commission approval for its Phesgo which is a combined dose of Perjeta and Herceptin used for the treatment of HER2 positive breast cancer. . Approval was granted based on the results of the pivotal phase 3 FeDeriCa trial which showed that Phesgo delivered a non-lower level of Perjeta and Herceptin into the blood compared to the IV formulation, it showed safety and efficacy of Phesgo.

Main characteristics of the study:

  • This report provides an in-depth analysis of the Global Specialty Injectables Market, Market Size (USD Billion) and Compound Annual Growth Rate (CAGR%) for the forecast period (2021-2028), looking to 2020 as the reference year.
  • It elucidates potential revenue opportunities across different segments and explains an attractive investment proposition matrix for this market.
  • This study also provides key insights into the market drivers, restraints, opportunities, new product launches or approvals, regional outlook, and competitive strategies adopted by key players.
  • It profiles leading players of the global Specialty Injectables market based on the following parameters: Company Overview, Financial Performance, Product Portfolio, Geographical Presence, Distribution Strategies, Key Developments & Strategies and Future Plans
  • The main companies covered in this study are Pfizer Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Novartis AG, Baxter International Inc., Mylan NV, Merck & Co. Inc., Fresenius SE & Co. KGaA , Endo International Plc., AstraZeneca, Hikma Pharmaceuticals PLC, Lupine Ltd., Genentech USA Inc., Sagent Pharmaceuticals Inc., Cipla Limited, Sun Pharmaceutical Industries Limited, Genzyme Corporation, Dr Reddy’s Laboratories, Biogen, Alnylam Pharmaceuticals Inc. and Amgen Inc. .
  • The information in this report would enable marketers and managing authorities of companies to make informed decisions regarding their future product launch, technology upgrade, market expansion and marketing tactics.
  • The Global Specialty Injectables Market report is targeted at various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants and financial analysts.
  • Stakeholders would have an ease in decision-making through various strategic matrices used to analyze the Specialty Injectables market

Main topics covered:

1. Research objectives and hypotheses

2. Market Overview

  • Description of the report
  • Market definition and scope
  • Summary
  • Market Extract, By Drug Type
  • Market Extract, By Application
  • Market extract, by distribution channel
  • Market extract, by region
  • Map of opportunities for publishers

3. Market dynamics, regulation and trend analysis

  • Market dynamics
  • Drivers
  • Constraints
  • Market opportunities
  • Impact analysis
  • Regulatory scenario
  • PEST analysis
  • Recent product launch/approval
  • Epidemiology
  • Mergers and Acquisitions

4. COVID – 19 Impact Analysis

  • Supply chain impact
  • Impact on research and development
  • Government initiatives

5. Global Specialty Injectables Market, by Drug Type, 2017-2028 (USD Billion)

  • Introduction
  • Market share analysis, 2021 and 2028 (%)
  • Annual Growth Analysis, 2018 – 2028
  • Industry trends
  • Small molecule drugs
  • Introduction
  • Market size and forecast, and annual growth, 2018-2028, (USD billion)
  • Organic Products
  • Introduction
  • Market size and forecast, and annual growth, 2018-2028, (USD billion)

6. Global Specialty Injectables Market, by Application, 2017-2028 (USD Billion)

  • Introduction
  • Market share analysis, 2021 and 2028 (%)
  • Annual Growth Analysis, 2018 – 2028
  • Industry trends
  • Oncology
  • Introduction
  • Market size and forecast, and annual growth, 2018-2028, (USD billion)
  • Cardiovascular illnesses
  • Introduction
  • Market size and forecast, and annual growth, 2018-2028, (USD billion)
  • Central nervous system diseases
  • Introduction
  • Market size and forecast, and annual growth, 2018-2028, (USD billion)
  • Infectious diseases
  • Introduction
  • Market size and forecast, and annual growth, 2018-2028, (USD billion)
  • Autoimmune disorders
  • Introduction
  • Market size and forecast, and annual growth, 2018-2028, (USD billion)
  • Others
  • Introduction
  • Market size and forecast, and annual growth, 2018-2028, (USD billion)

7. Global specialty injectables market, by distribution channel, 2017-2028 (USD billion)

  • Introduction
  • Market share analysis, 2021 and 2028 (%)
  • Annual Growth Analysis, 2018 – 2028
  • Industry trends
  • Hospital pharmacies
  • Introduction
  • Market size and forecast, and annual growth, 2018-2028, (USD billion)
  • Specialized pharmacies
  • Introduction
  • Market size and forecast, and annual growth, 2018-2028, (USD billion)
  • Online pharmacies
  • Introduction
  • Market size and forecast, and annual growth, 2018-2028, (USD billion)

8. Global Specialty Injectables Market, by Region, 2017-2028 (USD Billion)

9. Competitive landscape

  • Company Profiles
  • Pfizer Inc.
  • Company presentation
  • Drug portfolio
  • Financial performance
  • Recent developments/updates
  • Strategies
  • Eli Lilly and company
  • Company presentation
  • Drug portfolio
  • Financial performance
  • Recent developments/updates
  • Strategies
  • Teva Pharmaceutical Industries Ltd.
  • Company presentation
  • Drug portfolio
  • Financial performance
  • Recent developments/updates
  • Strategies
  • Novartis AG
  • Company presentation
  • Drug portfolio
  • Financial performance
  • Recent developments/updates
  • Strategies
  • Baxter International Inc.
  • Company presentation
  • Drug portfolio
  • Financial performance
  • Recent developments/updates
  • Strategies
  • Mylan AG
  • Company presentation
  • Drug portfolio
  • Financial performance
  • Recent developments/updates
  • Strategies
  • Merck & Co. Inc.
  • Company presentation
  • Drug portfolio
  • Financial performance
  • Recent developments/updates
  • Strategies
  • Endo International Plc.
  • Company presentation
  • Drug portfolio
  • Financial performance
  • Recent developments/updates
  • Strategies
  • Astra Zeneca
  • Company presentation
  • Drug portfolio
  • Financial performance
  • Recent developments/updates
  • Strategies
  • Hikma Pharmaceuticals PLC
  • Company presentation
  • Drug portfolio
  • Financial performance
  • Recent developments/updates
  • Strategies
  • Lupine Ltd.
  • Company presentation
  • Drug portfolio
  • Financial performance
  • Recent developments/updates
  • Strategies
  • Genentech USA Inc.
  • Company presentation
  • Drug portfolio
  • Financial performance
  • Recent developments/updates
  • Strategies
  • Sagent Pharmaceuticals Inc.
  • Company presentation
  • Drug portfolio
  • Financial performance
  • Recent developments/updates
  • Strategies
  • Cipla Limited
  • Company presentation
  • Drug portfolio
  • Financial performance
  • Recent developments/updates
  • Strategies
  • Fresenius SE & Co. KGaA
  • Company presentation
  • Drug portfolio
  • Financial performance
  • Recent developments/updates
  • Strategies
  • Sun Pharmaceutical Industries Limited
  • Company presentation
  • Drug portfolio
  • Financial performance
  • Recent developments/updates
  • Strategies
  • Dr. Reddy’s Laboratories
  • Company presentation
  • Drug portfolio
  • Financial performance
  • Recent developments/updates
  • Strategies
  • biogenic
  • Company presentation
  • Drug portfolio
  • Financial performance
  • Recent developments/updates
  • Strategies
  • Alnylam Pharmaceuticals Inc.
  • Company presentation
  • Drug portfolio
  • Financial performance
  • Recent developments/updates
  • Strategies
  • Amgen Inc.
  • Company presentation
  • Drug portfolio
  • Financial performance
  • Recent developments/updates
  • Strategies
  • Genzyme Company
  • Company presentation
  • Drug portfolio
  • Financial performance
  • Recent developments/updates
  • Strategies
  • Analyst Views

10. Branch

For more information on this report, visit https://www.researchandmarkets.com/r/kds4hb


CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

main logo

Share.

Comments are closed.